HansaBioMed Life Sciences LTD
Mäealuse 2/1, 12618 Tallinn (EE)
Phone: +372 6561996
email: info@hansabiomed.eu
www.hansabiomed.eu

Pioneering the EV fieldHansaBioMed Life Sciences launches Puriﬁed Extracellular Vesicles from Human Platelets,developed in collaboration with Finnish Red Cross Blood Service
Tallinn, Estonia – [03/09/2024] – HansaBioMed Life Sciences, a pioneer in the ﬁeld of extracellular vesicles (EVs), is proud
to announce the launch of its latest product: puriﬁed Extracellular Vesicles from Human Platelets. This product, developed incollaboration with the Finnish Red Cross Blood Service (FRCBS), represents a signiﬁcant advancement in the standardization,
control, and purity of EVs from human bioﬂuids available on the market.
The partnership between HansaBioMed and FRCBS, which began in 2021, was established with the shared goal of oﬀering highly
characterized and standardized EV material from Blood components to the life science research and development. The newly
released EVs from Human Platelets set a new benchmark in the ﬁeld, oﬀering researchers superior quality and reliability comparedto existing EV products.
“The current reference materials in the EV research ﬁeld require continuous improvement and innovation,” said Dr. Paolo Guazzi,Chief Operating Oﬃcer of HansaBioMed Life Sciences. “Our collaboration with FRCBS, a highly experienced blood center, andDr Saara Laitinen is essential to achieving the next generation of EVs from blood components. These EVs are highly characterizedand standardized, both in the preanalytical processing of raw material and downstream EV puriﬁcation. The ﬁnal product will bea valuable aid for researchers seeking to unlock the potential of blood derived EVs.”
Extracellular vesicles are very abundant in blood. Blood is known to be very complex ﬂuidic tissue and it contains many othernanoscale particles such as lipoprotein particles that share properties with EVs like size and lipophilicity. These possesse a challenge
for puriﬁcation and manufacturing.
“Blood service has decades of experience in separating cells and other vital components from donated whole blood, which oﬀers
a unique expertise and helps include EV isolation into its processes,” said Dr. Laitinen, R&D Manager of FRCBS Research Unit.
“To diminish the heterogeneity of the starting material we specially isolate platelet derived EVs from already existing pre-puriﬁed
platelet concentrates and not from plasma or whole blood. We use excess material from the routine process not risking the clinicaluse of the donated blood. Our approach is ethically guided and bases on pools of residual components that ensures that the ﬁnal
product is untraceable to individual donors,” she further explains.
“HansaBioMed has a strong reputation in high-quality EV products and as a pioneering company in the ﬁeld appreciates thetedious work behind each patch of EVs. Thus, it was easy to choose HansaBioMed as our collaborator for global distribution. We
hope that our blood cell driven EVs will help scientists to learn more of their role in cell-to-cell communication and further help todevelop lifesaving therapeutics for the beneﬁt of the patient.”
For more information about HansaBioMed Life Sciences and its products, please visit www.hansabiomed.eu.
About HansaBioMed Life Sciences: HansaBioMed Life Sciences is the oldest company globally that is fully dedicated to theresearch and development of products in the ﬁeld of extracellular vesicles. The company is actively involved in research projects
that explore the full potential of EVs while providing high-quality products to support nanoparticle and EV research.
About Finnish Red Cross Blood Service: Finnish Red Cross Blood Service (FRCBS) has been performing active scientiﬁc research
for more than 70 years. Blood Service R&D can be divided into strategic focus areas: the eﬀectiveness of the blood supply chain,cell and tissue compatibility, and the development of products and services. FRCBS holds a solid position in developing EV-based
technologies.

HansaBioMed Life Sciences contact details:
Paolo Guazzi, Chief Operating Oﬃcer
paolo.guazzi@hansabiomed.eu+372 6561996

Finnish red Cross Blood Service (FRCBS) contact details:
Saara Laitinen, R&D manager
Saara.Laitinen@veripalvelu.ﬁ+358 29-300 1695